BrisSynBio start-up, Zentraxa has been named 'Best South-West England SynBio Start-up' at the 2017 Bio-start Awards, winning three months of free laboratory space at Bristol-based innovation centre, Unit DX.
Reaching net zero carbon dioxide emissions, eliminating hunger and poverty, tackling misinformation and vaccine hesitancy, decolonisation, and overcoming the digital divide are among key topics set to take centre stage at the inaugural University of Bristol Festival of International Research and Partnerships, which starts next week.
The human stories behind Bristol scientists who are playing an important role in global efforts to overcome COVID-19 have been captured in a billboard campaign by a Bristol-based photographer.
Scientists from the University of Bristol have designed a new protein structure, and are using it to understand how protein structures are stabilised.
Representatives from the French Embassy visited University labs today [10 December] to see some of the innovative COVID-19 research being undertaken at Bristol, including work on ADDomer™, a thermostable vaccine platform being developed by Bristol scientists to combat emerging infectious diseases.
Artificial cells capable of oxygen gas production and chemical signalling have been prepared using a combination of synthetic and biological catalysts through an international collaboration between the University of Bristol and the University of Padua in Italy.
Faster vaccine development could be a step closer thanks to £4 million investment to Imophoron Ltd, a Bristol University biotech start-up developing a novel, next generation rapid-response vaccine platform called ADDomer™. Imophoron will use the investment to bring ADDomer vaccines to clinical stage, initially targeting three viruses, RSV (respiratory syncytial virus), COVID-19, and mosquito-borne Chikungunya.
Combining the innovations of synthetic biology with robotic environmental sampling, a team of University of Bristol researchers are travelling to some of the most ‘extreme’ environments on Earth, including Atlantic depths of 4.5km, to find new leads which could help in the global fight against antimicrobial resistance.
The University of Bristol and spin-out company Imophoron have announced they are ready to test COVID-19 vaccine candidates in a pre-clinical programme.
A team of scientists, led by the University of Bristol, has developed a new photosynthetic protein system enabling an enhanced and more sustainable approach to solar-powered technological devices.
